Equitable Holdings, Inc. Sellas Life Sciences Group, Inc. Transaction History

Equitable Holdings, Inc.

$10.1 Billion
Q4 2024

A detailed history of Equitable Holdings, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Equitable Holdings, Inc. holds 12,060 shares of SLS stock, worth $14,592. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,060

Previous 12,060 -0.0%

Holding current value

$14,592

Previous $15,000 20.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.08 - $1.39 $213,775 - $275,136	-197,940 Reduced 94.26%	12,060 $15,000
Q2 2024 Aug 14, 2024	BUY	$1.06 - $1.63 $10,600 - $16,299	10,000 Added 5.0%	210,000 $249,000
Q1 2024 May 14, 2024	BUY	$0.51 - $1.55 $17,850 - $54,250	35,000 Added 21.21%	200,000 $202,000
Q4 2023 Feb 12, 2024	BUY	$0.88 - $1.57 $26,400 - $47,100	30,000 Added 22.22%	165,000 $174,000
Q2 2023 Aug 15, 2023	BUY	$1.35 - $1.8 $6,750 - $9,000	5,000 Added 3.85%	135,000 $211,000
Q1 2023 May 15, 2023	BUY	$1.18 - $3.86 $20,060 - $65,620	17,000 Added 15.04%	130,000 $185,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $5.41 $5,400 - $16,230	3,000 Added 2.73%	113,000 $266,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $4.15 $12,840 - $24,900	6,000 Added 5.77%	110,000 $245,000
Q1 2022 May 13, 2022	BUY	$4.73 - $7.18 $9,460 - $14,360	2,000 Added 1.96%	104,000 $695,000
Q4 2021 Feb 11, 2022	BUY	$5.36 - $9.53 $10,720 - $19,060	2,000 Added 2.0%	102,000 $564,000
Q3 2021 Nov 12, 2021	BUY	$8.21 - $10.53 $46,797 - $60,020	5,700 Added 6.04%	100,000 $916,000
Q4 2020 Feb 09, 2021	BUY	$2.45 - $17.66 $83,300 - $600,440	34,000 Added 56.38%	94,300 $548,000
Q3 2020 Nov 13, 2020	BUY	$1.88 - $3.58 $113,364 - $215,874	60,300 New	60,300 $160,000

Others Institutions Holding SLS

# of Institutions

Shares Held

6.49M

Call Options Held

1.8M

Put Options Held

49.7K

View Full List

About SELLAS Life Sciences Group, Inc.

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $24.9M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

More about SLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Equitable Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Equitable Holdings, Inc. with notifications on news.

Account

Equitable Holdings, Inc. Sellas Life Sciences Group, Inc. Transaction History